Russia Meningococcal Vaccines Market Size & Outlook
Russia meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
Russia meningococcal vaccines market highlights
- The Russia meningococcal vaccines market generated a revenue of USD 14.4 million in 2021 and is expected to reach USD 27.4 million by 2030.
- The Russia market is expected to grow at a CAGR of 7.4% from 2022 to 2030.
- In terms of segment, quadrivalent was the largest revenue generating type in 2021.
- Quadrivalent is the most lucrative type segment registering the fastest growth during the forecast period.
Meningococcal vaccines market data book summary
| Market revenue in 2021 | USD 14.4 million |
| Market revenue in 2030 | USD 27.4 million |
| Growth rate | 7.4% (CAGR from 2021 to 2030) |
| Largest segment | Quadrivalent |
| Fastest growing segment | Quadrivalent |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, Russia accounted for 0.5% of the global meningococcal vaccines market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK meningococcal vaccines market is projected to lead the regional market in terms of revenue in 2030.
- Russia is the fastest growing regional market in Europe and is projected to reach USD 27.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Russia meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Quadrivalent was the largest segment with a revenue share of 66.67% in 2021. Horizon Databook has segmented the Russia meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
The meningococcal vaccines market in Russia is estimated to witness significant growth rate during the forecast period. Increasing awareness about meningitis is expected to drive the market. The incidence of IMD is around 0.48 per 100,000 population in the country. Moreover, the presence of local players such as Microgen developing new meningococcal vaccine is also anticipated to boost market growth.
In February 2021, the Ministry of Health, Russia, registered new vaccine for meningococcal A & C infections, produced by Microgen. Moreover, in November 2019, Sanofi and Nanotek partnered to localize the production of combined conjugate vaccine against meningococcal infection.
According to a study conducted in Moscow to identify epidemiological features of meningococcal infection related to recommendation of vaccination against meningococcal disease by including total population recommended the introduction of vaccination into the National Immunization Program in the country.
Reasons to subscribe to Russia meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Russia meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Russia meningococcal vaccines market , including forecasts for subscribers. This country databook contains high-level insights into Russia meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Russia meningococcal vaccines market size, by type, 2018-2030 (US$M)
Russia Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
